PATENT CLAIM ANALYSIS

Application Number: 15934246
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-08
Patent Classification: ["514", "414000"]

Abstract:
Uses of compound of Formula I: or pharmaceutically acceptable enantiomers, salts, solvates or prodrugs thereof are described. The compounds of Formula I are useful as IDO1 inhibitors. These are also useful for the treatment and/or prevention of cancer and endometriosis.

Claim (Index 2):
The method according to  claim 1 , wherein the brain cancer is selected from glioblastomas and medulloblastomas; the intraepithelial neoplasms is selected from Bowen's disease and Paget's disease; the oral cancer is squamous cell carcinoma; the ovarian cancer is selected from those arising from epithelial cells, stromal cells, germ cells and mesenchymal cells; the renal cancer is selected from adenocarcinoma and Wilms tumor; the sarcomas is selected from leiomyosarcoma, rhabdomyosarcoma, liposarcoma, fibrosarcoma and osteosarcoma; the skin cancer is selected from melanoma, Kaposi's sarcoma, basocellular cancer and squamous cell cancer; the testicular cancer is selected from germinal tumors seminomas, and non-seminomas selected from teratomas and choriocarcinomas; and the thyroid cancer is selected from thyroid adenocarcinoma and medullary carcinoma.

Metadata:
- Claim Count in Document: 50.0
- Percentile: 90.0
- Lexical Diversity: 1.35294
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['15331446', '14711911', '14215852', '11350335', '13761712']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7911150337107843
- 35 USC 102 Novelty (BERT): 0.5843979237097815
- Combined Prediction Score: 0.770443322710684
- Mean Citation Score: 415.51952200000005
- Max Citation Score: 548.4024
- Similarity Product: 364.5566296351432

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test